GMP Facilities for Cell Therapy — What CBER’s Facility Inspection Will Look For

A cell therapy BLA without a facility that passes inspection is a submission, not an approval. Understanding what CBER inspectors evaluate before you build or validate your facility is the only way to avoid a manufacturing hold.

Most cell therapy programs treat facility compliance as a manufacturing operations problem — something to be managed by the quality team in the final twelve months before BLA submission. That framing is exactly why pre-license inspection findings generate manufacturing holds that delay approvals by a year or more. CBER’s pre-approval inspection for cell therapy products is a regulatory adjudication of whether your facility, systems, and personnel can reproducibly manufacture a living-cell product that meets the standards described in your BLA — and the facility strategy that survives that adjudication must be built years before the inspection request is filed, not assembled in the sprint to submission.

The GMP Facility Requirements for Cell Therapy: What CBER’s Facility Inspection Assesses

CBER’s facility inspection framework for cell therapy products draws from multiple regulatory layers simultaneously: 21 CFR 210/211 (cGMP for finished pharmaceuticals), 21 CFR 600 (biological products standards), 21 CFR 610 (general biological product standards including adventitious agent testing requirements under 21 CFR 610.18), and — critically for any facility handling donor-sourced starting materials — 21 CFR Part 1271 (human cells, tissues, and cellular and tissue-based products). No single regulation governs the complete inspection scope; CBER inspectors work across all of these, and a facility that is fully compliant with 21 CFR 211 but deficient in its 21 CFR Part 1271 donor eligibility testing panel will receive findings that can delay licensure regardless of manufacturing quality.

The donor eligibility testing requirements under 21 CFR 1271.85 define a specific panel that must be executed for donor material used in allogeneic products: anti-HIV-1/2, anti-HTLV-I/II, HBsAg, anti-HBc (both IgM and total), anti-HCV, nucleic acid testing for HIV-1 RNA, HCV RNA, and HBV DNA, anti-Treponema pallidum, West Nile Virus NAT, and Trypanosoma cruzi antibody for applicable geographic regions. CMV testing is required for allogeneic hematopoietic stem cell products and considered risk-based for other allogeneic programs. Inspectors will examine the SOP governing donor eligibility determination, the laboratory performing the testing, and whether test results are properly linked to the specific donor lot through chain-of-identity records. A facility that cannot produce a closed, auditable chain connecting a donor test result to the final patient product lot will receive a critical observation.

For programs manufacturing products from oncology patients — CAR-T for ALL, TIL for solid tumors — CBER’s inspection focus extends to tumor cell contamination testing. The required strategy includes karyotype analysis to identify abnormal clones distinguishable from the donor background, flow cytometry using lineage markers appropriate to the tumor type (CD45+/−, GD2 for neuroblastoma, CD19 for B-ALL), and qPCR for tumor-specific fusion genes such as BCR-ABL or EWS-FLI1 where applicable. For CAR-T products manufactured from ALL patients, residual tumor cell testing is a mandatory lot release component — not a risk-based decision the sponsor can defer — because leukemic blasts can co-purify with T cells during leukapheresis and potentially survive ex vivo expansion conditions.

Cleanroom Design, HVAC, and the Aseptic Processing Requirements for Autologous and Allogeneic CT

Cell therapy products are manufactured under aseptic conditions across the entire manufacturing sequence — from receipt of leukapheresis material through cell activation, transduction, expansion, harvest, formulation, and cryopreservation. FDA’s Guidance for Industry: Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) (finalized December 2011) establishes CGTP requirements for the processing environment, while aseptic processing standards governing the final drug product derive from 21 CFR 211.42 and the established expectations for sterile pharmaceutical manufacturing. CBER facility inspectors evaluating a cell therapy manufacturing suite assess whether the aseptic process simulation program — the media fill — has been designed to represent the specific interventions that occur during cell therapy manufacturing rather than a generic sterile fill operation. This is consistently the highest-yield inspection deficiency area for cell therapy PAIs.

A concrete illustration of how this deficiency manifests: a CAR-T manufacturing program validates its media fill using a standard parenteral fill-finish simulation — sealed vials, automated filling line, limited manual interventions — without incorporating the open cell washing steps, lentiviral vector addition into an open culture vessel, or harvest bag spike that occur during actual manufacturing. When the inspector compares the APS intervention log to the manufacturing batch record, the representativeness gap is immediately apparent. EudraLex Volume 4, Part IV (the EU GMP guidelines specific to ATMPs), establishes that APS programs must reflect all interventions and environmental conditions encountered during routine manufacture — a standard CBER inspectors apply with equivalent rigor, supported by the operational guidance in the ISPE Guides on Advanced Therapy Medicinal Products (Autologous Cell Therapy and Allogeneic Cell Therapy) on mapping process-specific interventions into the media fill design.

For iPSC-derived cell therapy products, facility qualification demands extend into tumorigenicity control. Current FDA expectations for pluripotent-cell-derived products (informed by CBER’s cell therapy CMC guidance and international consensus recommendations, including HESI’s International Cell Therapy Committee guidance on teratoma/tumorigenicity risk assessment) call for negative results in both an in vivo tumorigenicity study (commonly using immunocompromised NSG or NOG mice with an observation period on the order of six months) and an in vitro soft agar colony formation assay (or comparable anchorage-independent growth assay) before clinical use; no single, specifically-titled 2008 FDA guidance document establishes this requirement, and the expectation instead reflects a body of current regulatory science and published consensus recommendations. Inspectors evaluating an iPSC-derived program will ask for the tumorigenicity testing SOPs, the NSG mouse study protocol, and the release specification that gates lot disposition on a negative colony formation result — verified as qualified in the commercial facility.

Contamination Control Strategy for Cell Therapy Facilities: The Segregation and HVAC Requirements

Contamination control for cell therapy facilities operates at two levels evaluated separately by CBER: microbiological contamination control (aseptic processing, environmental monitoring) and cross-contamination control between patient lots or donor materials. For allogeneic products, cross-contamination between donor lots is a CMC deficiency; for autologous products where multiple patient lots may be in process simultaneously, it is also a direct patient safety concern with chain-of-identity and product mix-up implications.

The environmental monitoring program for a cell therapy facility must include viable particle trend analysis — not just enumeration at individual time points. CBER inspectors reviewing environmental monitoring programs look for evidence that the facility is conducting longitudinal trend analysis of viable airborne particle counts, surface monitoring data, and personnel monitoring results, and that excursion investigations are documented with root cause analysis and CAPA. A program that enumerates viable particles at each monitoring interval but does not trend those data, assess them for statistical signals, or use them to inform facility qualification status decisions is operationally deficient under 21 CFR 211.68 and the FDA Process Validation Guidance (2011), which establishes the expectation for continued process verification including environmental monitoring as a standing quality system output — not a periodic sampling exercise.

For autologous programs processing multiple patient lots simultaneously, the segregation strategy is inspected with the same rigor as the APS program. CBER inspectors will request the validated segregation procedure and expect evidence that it has been tested under conditions representative of maximum concurrent patient lot processing. This includes not just physical segregation of suites or biosafety cabinets but also the electronic and manual controls governing label reconciliation, lot traveler management, and the final release check confirming the product being released matches the patient for whom it was manufactured. Cell senescence testing adds a further quality anchor for expanded cell populations: SA-β-galactosidase staining (identifying cells arrested in G0/G1), telomere length analysis by qPCR (with shortened telomeres correlating with replicative senescence and reduced in vivo persistence), and reactive oxygen species measurement by CellROX flow assay must be qualified in the facility performing lot release — and the facility’s analytical equipment qualification must cover the instrumentation supporting these assays.

Designing a Cell Therapy Manufacturing Facility That Will Pass CBER Pre-License Inspection

The XGene Cell Therapy Facility GMP Compliance and Inspection Readiness Assessment is a structured pre-inspection readiness framework built specifically for cell therapy manufacturing facilities approaching BLA submission or pre-license inspection, evaluating cleanroom qualification, APS program design, equipment qualification, environmental monitoring, segregation strategy, and biosafety compliance against CBER inspection expectations.

1. Cleanroom and HVAC Qualification Gap Analysis. Map every ISO classification boundary in the manufacturing suite against the specific process steps performed in each zone; verify that Grade A/ISO 5 qualification data cover the actual critical manipulation points rather than only the general suite classification; and confirm that HVAC pressure cascade documentation demonstrates uninterrupted segregation under operational conditions including door openings and personnel transfer — producing a qualification evidence matrix referenced directly to the BLA CMC facility description.

2. Aseptic Process Simulation Representativeness Audit. Pull the most recent APS protocol and compare the documented interventions against the current manufacturing batch record to identify process steps that occur open to the environment but were not simulated — open cell washes, bioreactor inoculations, harvest bag spike and transfer — and determine whether a supplemental simulation is required before the inspection request is submitted, with a written rationale that pre-empts the inspector’s representativeness question.

3. Donor Eligibility and Chain-of-Identity Record Trace. For every donor lot or autologous patient material in the facility’s current manufacturing inventory, trace the 21 CFR 1271.85 testing panel from the original test result through the donor eligibility determination SOP to the manufacturing batch record and the chain-of-identity label affixed to the final product, verifying that no gap exists at any hand-off point and that the complete record chain can be produced without additional retrieval during an inspection.

4. Segregation Validation and Concurrent Lot Processing Evidence Package. For autologous programs, assemble validation data supporting maximum concurrent patient lot processing — including label reconciliation records, suite assignment logs, equipment dedication documentation, and the final release check audit trail — formatted as a continuous chain from leukapheresis receipt to final product disposition that an inspector can follow without requesting supplemental records.

The output of this assessment is a pre-inspection evidence dossier that maps each CFR citation and CBER inspection focus area to a specific document, record, or qualified procedure — not a gap list requiring remediation, but a close-out package demonstrating that every inspection anchor point is substantiated before the inspector walks through the door.

A cell therapy program that reaches BLA submission without a facility prospectively assessed against CBER’s inspection expectations is exposing itself to a manufacturing hold that no amount of post-submission remediation can resolve quickly. The corrective actions required — APS redesign and re-execution, environmental monitoring system remediation, facility requalification, or bioreactor re-validation — each require months of execution before CBER will consider the matter closed, and those months come directly out of the approval timeline. For programs operating on investor-funded runways, a manufacturing hold triggered by a facility deficiency that was visible and addressable during process development is not a regulatory setback — it is a preventable strategic failure. The regulatory framework governing cell therapy facility compliance, from 21 CFR 210/211 through 21 CFR Part 1271 and 21 CFR 610, is unambiguous about what is required; the programs that pass inspection are those that built and documented compliance prospectively rather than assembled it under the pressure of an approaching inspection date.

For your cell therapy manufacturing facility, can you identify today the most recent aseptic process simulation (media fill) report including the number of units filled, the interventions simulated, and the outcome — and whether the simulation design included the specific process interventions unique to your cell therapy manufacturing process?